Debiopharm International
Diamond Sponsor
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing new antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing early stage through phase II research of novel, pathogen-specific antibiotics, with afabicin, specifically targeting staphylococci spp., being the most clinically advanced for the treatment of Bone & Joint infections. As a result of highly selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota while meeting all four WHO 2020 innovativeness criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
GET INVOLVED AT THE
WORLD ANTI-MICROBIAL RESISTANCE CONGRESS
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events